Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
AKI
alanine aminotransferase (ALT)
alanine transaminase (ALT)
aldehyde dehydrogenase (ALDH)
ALDH
ALK
Alkylating agents cyclophosphamide and ifosfamide ethylenimines methylguanine methyltransferase, clinical importance nitrosoureas platinum compounds treatment goal triazines (three attached nitrogen atoms)
ALL
allo-hematopoietic stem cell transplantation (HSCT) Answer 15.3 Answer 15.4 Answer 15.5 Mechanism of Action of High-Dose Cyclophosphamide Graft-Versus-Host Disease (GVHD) Prophylaxis Question 15.1 Question 15.2 Question 15.3 Question 15.4 Transplant-Related Agents
all-trans retinoic acid (ATRA) Answer 8.2 Differentiating Agents and Microenvironment Question 8.1
α-ketoglutarate (α-KG)
α-KG
ALT
American Society of Clinical Oncology (ASCO)
aminotransferase (AST)
AML
anaplastic lymphoma kinase (ALK) Anaplastic Lymphoma Kinase (ALK) Fusion Targeted Therapies (Small Molecules)
ANC
and rogen deprivation therapy (ADT) Male Hormonal Therapies Overview of Prostate Cancer (PC) Progression and Treatment Question 10.2
and rogen receptor (AR) Male Hormonal Therapies Molecular Mechanism of and rogen Receptor (AR) Activation by Dihydrotestosterone (DHT) Physiological and Anatomical Targets of FDA-Approved "Hormonal" Drugs for Prostate Cancer
and rogen response element (ARE)
antibody-dependent cell-mediated cytotoxicity (ADCC) Components of 90y-Ibritumomab Tiuxetan Naked Monoclonal Antibody Mechanism of Action Novel Therapeutic Strategies in Oncology
antibody-dependent cellular cytotoxicity (ADCC)
antibody-dependent cellular phagocytosis (ADCP)
antibody-drug conjugates (ADC) Monoclonal Antibodies Including Immunoconjugates and Cytokine-Directed Agents Multiple Myeloma as a Paradigm for Multi-Targeted Intervention
Anticancer drug development limitations to effective action overview pathophysiology of cancer pharmacokinetics targets treatment goal usefulness usefulness\|Kaplan-meier method, survival in the two groups work at all, stop working, or never work?
Antifolates absorption and elimination action mechanism adverse events folate transporters overview relative affinities of folate receptor (FR) and reduced folate carrier (RFC) toxicity and rescue toxicity and rescue\|leucovorin (LV) "rescue" in high-dose MTX toxicity and rescue\|MTX breakdown via glucarpidase toxicity and rescue\|THF compared to leucovorin (folinic acid, LV) structure toxicity and rescue\|urinary excretion of high-dose MTX and effect of medications and urine pH treatment goal
antigen-presenting cells (APCs)
Antimetabolites classification overview treatment goal
Antimitotics adverse events related to vinca alkaloids chromosome cycle eribulin ixabepilone microtubule-directed agents microtubules taxanes, adverse events treatment goal vinca alkaloids and neurotoxicity